Every so often, a press release actually earns the word "landmark," and this was one of those weeks. On August 19, Merck and Moderna announced that a personalized mRNA cancer vaccine, combined with Merck's blockbuster immunotherapy Keytruda, had hit its primary and key secondary endpoints in a Phase 3 trial for high-risk melanoma patients whose tumors had been surgically removed. It's the first positive late-stage result ever recorded for an individualized neoantigen therapy, and the first for any mRNA-based cancer treatment, full stop. Merck's stock jumped on the news. The question worth asking now is whether it should keep climbing — and on that, the honest answer is more complicated than the headline.
What Actually Happened in the Trial
Let's be precise about this, because precision is exactly what's still missing from the public data. The trial, called INTerpath-001, enrolled 1,137 patients with completely resected stage IIB through IV cutaneous melanoma — meaning the visible tumor had already been cut out surgically, and the treatment's job was to stop it from coming back. Patients were randomized roughly two-to-one to receive either the personalized vaccine, intismeran autogene, alongside Keytruda, or Keytruda by itself, for about a year. At a prespecified interim analysis, the combination produced statistically significant, clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone. No new safety signals turned up.
This is not, and was never intended to be, a preventive vaccine against skin cancer showing up on shelves next to a flu shot. It's a highly personalized therapy, manufactured individually for each patient based on the specific mutations found in their own resected tumor — genuinely novel science, but also inherently more complex and expensive to deliver than a standard drug. The companies haven't released the actual numbers yet — hazard ratios, magnitude of benefit, follow-up duration — reserving that for an upcoming medical conference. Everything the market is currently pricing in is based on a topline "it worked," not the data that will actually determine how meaningful "worked" turns out to be.
For context on what "meaningful" might look like: an earlier Phase 2 trial of the same combination, in 157 patients, cut the relative risk of death or recurrence by 44% versus Keytruda alone. Keytruda by itself, in its original pivotal trial, reduced that risk by 43% versus a placebo arm with no immunotherapy at all. If the Phase 3 confirms anything close to that Phase 2 magnitude, this is a genuine step change in how high-risk melanoma gets treated after surgery — not an incremental tweak.
Why Merck Needed a Win Like This
Here's the part of the story that doesn't show up in the celebratory press coverage: Merck has one of the most concentrated single-product revenue profiles of any major pharmaceutical company, and the product in question is Keytruda. The drug generated $29.5 billion in 2024, close to half of Merck's total revenue, and its core U.S. composition-of-matter patent is set to expire in 2028 — an event industry analysts have taken to calling the single largest patent cliff in oncology history. Without a defense, some estimates put Keytruda's post-2028 revenue erosion at roughly 80%, a drop from around $30 billion to something closer to $6 billion annually.
Merck's primary defense so far has been Keytruda Qlex, an FDA-approved subcutaneous formulation with its own separate patent estate that CEO Rob Davis has described as turning the patent cliff into "more of a hill." The company is targeting something like 30-40% conversion of Keytruda's U.S. patient base onto the subcutaneous version by 2027 — a meaningful cushion, but a cushion, not a replacement.
This is where the melanoma vaccine data actually matters strategically, and it's a subtler argument than "great trial result, buy the stock." A combination therapy that only works when paired with Keytruda gives oncologists — and payers — a fresh clinical reason to keep prescribing Keytruda-based regimens even as biosimilar competitors enter the market in 2028 and beyond. It's not a new blockbuster in its own right so much as reinforcement for the existing one, extending Keytruda's clinical relevance in a specific, high-value indication at exactly the moment competitors will be trying to peel prescribers away on price alone.
What the Stock Move Actually Prices In
Melanoma is a relatively small slice of Merck's overall business in dollar terms — an estimated 112,000 new U.S. cases and more than 8,500 deaths are projected for 2026, a fraction of the patient population across Keytruda's more than 40 approved indications. So the rally isn't really about melanoma-specific revenue. It's the market updating its view on two things at once: proof that Merck and Moderna's decade-long bet on personalized neoantigen vaccines can actually clear a Phase 3 bar, and a data point suggesting Merck's pipeline has more Keytruda-adjacent ammunition than the bear case assumed.
Both of those updates are reasonable. Neither of them changes the fundamental 2028 math. Even in the best case where intismeran becomes a standard adjuvant regimen and the subcutaneous formulation hits its conversion targets, Merck is still walking into a period where its largest product faces its first real biosimilar competition, in a market that has never seen a checkpoint-inhibitor patent cliff of this scale before. This week's data makes that walk somewhat less perilous. It does not cancel the walk.
The Bottom Line
The INTerpath-001 result is a genuine scientific milestone, and Merck and Moderna have earned the "landmark" framing on the science alone — this validates a personalized-medicine approach oncologists have chased for over a decade. Whether it's a genuine inflection point for the stock is a different question, and one the market won't be able to fully answer until the detailed data — hazard ratios, durability, overall survival trends — actually comes out at the upcoming conference. Until then, what investors have is a well-designed trial that hit its endpoints, a modest but real reinforcement of Merck's Keytruda ecosystem heading into 2028, and a patent cliff that remains exactly as steep as it was the week before the announcement. Good news and an unsolved problem can be true about the same stock at the same time. This is one of those weeks.
This article is for informational purposes only and does not constitute investment advice.